Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Raül Ondoño"'
Autor:
Raimon Puig de la Bellacasa, José I. Borrell, Xavier Batllori, Jordi Teixidó, Oriol Vallcorba, Claudi de Rocafiguera, Raül Ondoño, Iñaki Galve, Cristina Puigjaner, Mercè Font-Bardia
Publikováno v:
Dipòsit Digital de la UB
Universidad de Barcelona
Universidad de Barcelona
Wheland intermediates are usually unstable compounds and only a few have been isolated at very low temperatures. During our work on tyrosine kinase inhibitors, we studied the bromination of 7 in order to obtain a dibromo substituted pyrido[2,3-d]pyri
Autor:
Iñaki, Galve, Raül, Ondoño, Claudi, de Rocafiguera, Raimon, Puig de la Bellacasa, Xavier, Batllori, Cristina, Puigjaner, Mercè, Font-Bardia, Oriol, Vallcorba, Jordi, Teixidó, José I, Borrell
Publikováno v:
Organicbiomolecular chemistry. 18(48)
Wheland intermediates are usually unstable compounds and only a few have been isolated at very low temperatures. During our work on tyrosine kinase inhibitors, we studied the bromination of 7 in order to obtain a dibromo substituted pyrido[2,3-d]pyri
Autor:
Alex Perálvarez-Marín, Ángel Lirio, Roger Estrada-Tejedor, Germana Falcone, Beatrice Cardinali, Claudia Provenzano, Manuel Pérez-Alonso, Raül Ondoño, Carlos Elvira, Elena Álvarez-Marimon, José I. Borrell
Publikováno v:
Computational and Structural Biotechnology Journal
Computational and Structural Biotechnology Journal, Vol 19, Iss, Pp 51-61 (2021)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Computational and Structural Biotechnology Journal, Vol 19, Iss, Pp 51-61 (2021)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Graphical abstract
Highlights • Drug design with rational methods, using structure-based methods. • Novel RNA binders based on pyrido[2,3-d]pyrimidin-7-(8H)-ones. • Myotonic Dystrophy type 1 small molecule drug discovery.
Myotonic Dys
Highlights • Drug design with rational methods, using structure-based methods. • Novel RNA binders based on pyrido[2,3-d]pyrimidin-7-(8H)-ones. • Myotonic Dystrophy type 1 small molecule drug discovery.
Myotonic Dys
Publikováno v:
Organic & Biomolecular Chemistry; 12/28/2020, Vol. 18 Issue 48, p9731-9736, 6p
Autor:
Galve, Iñaki, Ondoño, Raül, de Rocafiguera, Claudi, Puig de la Bellacasa, Raimon, Batllori, Xavier, Puigjaner, Cristina, Font-Bardia, Mercεave;, Vallcorba, Oriol, Teixidó, Jordi, Borrell, José I.
Publikováno v:
Organic & Biomolecular Chemistry; 12/28/2020, Vol. 18 Issue 48, p9810-9815, 6p
Autor:
Helesbeux, Jean-Jacques1 (AUTHOR) jean-jacques.helesbeux@univ-angers.fr, Carro, Laura2 (AUTHOR) l.carro@ucl.ac.uk, McCarthy, Florence O.3 (AUTHOR) f.mccarthy@ucc.ie, Moreira, Vânia M.4,5 (AUTHOR) vmoreira@ff.uc.pt, Giuntini, Francesca6 (AUTHOR) F.Giuntini@ljmu.ac.uk, O'Boyle, Niamh7 (AUTHOR) nioboyle@tcd.ie, Matthews, Susan E.8 (AUTHOR) susan.matthews@uea.ac.uk, Bayraktar, Gülşah9 (AUTHOR) gulsah.bayraktar@ege.edu.tr, Bertrand, Samuel10 (AUTHOR) samuel.bertrand@univ-nantes.fr, Rochais, Christophe11 (AUTHOR) christophe.rochais@unicaen.fr, Marchand, Pascal12 (AUTHOR) pascal.marchand@univ-nantes.fr
Publikováno v:
Pharmaceuticals (14248247). Dec2021, Vol. 14 Issue 12, p1278-1278. 1p.